The conventional treatment for the autoimmune bullous skin diseases is broad-spectrum
immunosuppressive regimen typically combining systemic corticosteroids with adjuvant …

Autoimmune blistering diseases are associated with autoantibodies to desmosomal
(pemphigus group) or hemidesmosomal proteins (autoimmune subepidermal blistering …

Background: Although rituximab is known to be effective in the treatment of pemphigus, its
role in subepidermal autoimmune blistering diseases is unclear and currently limited to off …

BACKGROUND: Rituximab has been increasingly used in autoimmune blistering
dermatoses, mainly in pemphigus. However, only a few larger case series are available on …

Rituximab is a chimeric human-mouse monoclonal anti-CD20 antibody initially developed to
treat B cell lymphoproliferative disorders (1). It is now increasingly being used for the …

Background Pemphigus vulgaris (PV) is a severe antibody-mediated autoimmune blistering
disease. Because some patients with PV do not enter into remission, despite the use of high …

The aim of the treatment in autoimmune blistering diseases (AIBDs) is to induce and
maintain remission, which clinically corresponds to the cessation of new vesicle formation …

We propose rituximab as a first-line therapy for pemphigus vulgaris and steroid-dependent
bullous pemphigoid with or without systemic steroids. A brief review of the literature …

Pemphigus vulgaris and pemphigus foliaceus are rare autoimmune blistering diseases of
obscure causes. The scientific bases for the therapy of these disorders have evolved in the …

Background Intolerably high doses of systemic corticosteroids and additional
immunosuppressants may be required to control disease activity in autoimmune bullous skin …